Mexazolam | CAS#31868-18-5 | Anxiety

MedKoo Cat#: 525625 | Name: Mexazolam

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mexazolam is a drug which is a benzodiazepine derivative. Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance. Mexazolam is metabolised via the CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam, but not the HMG-CoA reductase inhibitor pravastatin.

Chemical Structure

Mexazolam

CAS#31868-18-5

Theoretical Analysis

MedKoo Cat#: 525625

Name: Mexazolam

CAS#: 31868-18-5

Chemical Formula: C18H16Cl2N2O2

Exact Mass: 362.0589

Molecular Weight: 363.24

Elemental Analysis: C, 59.52; H, 4.44; Cl, 19.52; N, 7.71; O, 8.81

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CS386; CS-386; CS 386; Melex; Sedoxil; Mexazolam

IUPAC/Chemical Name

10-chloro-11b-(2-chlorophenyl)-3-methyl-2,3,7,11b-tetrahydrobenzo[f]oxazolo[3,2-d][1,4]diazepin-6(5H)-one

InChi Key

ANUCDXCTICZJRH-UHFFFAOYSA-N

InChi Code

InChI=1S/C18H16Cl2N2O2/c1-11-10-24-18(13-4-2-3-5-15(13)20)14-8-12(19)6-7-16(14)21-17(23)9-22(11)18/h2-8,11H,9-10H2,1H3,(H,21,23)

SMILES Code

O=C1NC2=CC=C(Cl)C=C2C(OCC3C)(C4=CC=CC=C4Cl)N3C1

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 363.24 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fernandes H, Moreira R. Mexazolam: clinical efficacy and tolerability in the treatment of anxiety. Neurol Ther. 2014 Mar 29;3(1):1-14. doi: 10.1007/s40120-014-0016-7. eCollection 2014 Jun. Review. PubMed PMID: 26000220; PubMed Central PMCID: PMC4381915. 2: Weon Cho C, Chul Shin S. Enhanced Controlled Transdermal Delivery of Mexazolam Using Ethylene-vinyl Acetate. Iran J Pharm Res. 2012 Winter;11(1):3-12. PubMed PMID: 25317180; PubMed Central PMCID: PMC3876569. 3: Ferreira L, Figueira ML, Bessa-Peixoto A, Marieiro A, Albuquerque R, Paz C, Cerqueira A, Damião P, Dolgner A, Dingemanse J. Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder. Clin Drug Investig. 2003;23(4):235-43. PubMed PMID: 17535036. 4: Ishigami M, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes. Drug Metab Dispos. 2002 Aug;30(8):904-10. PubMed PMID: 12124308. 5: Ishigami M, Honda T, Takasaki W, Ikeda T, Komai T, Ito K, Sugiyama Y. A comparison of the effects of 3-hydroxy-3-methylglutaryl-coenzyme a (HMG-CoA) reductase inhibitors on the CYP3A4-dependent oxidation of mexazolam in vitro. Drug Metab Dispos. 2001 Mar;29(3):282-8. PubMed PMID: 11181496. 6: Kurono Y, Kamiya K, Kuwayama T, Jinno Y, Yashiro T, Ikeda K. Kinetics and mechanism of the acid-base equilibrium of mexazolam and comparison with those of other commercial benzodiazepinooxazole drugs. Chem Pharm Bull (Tokyo). 1987 Sep;35(9):3831-7. PubMed PMID: 2893667.